Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis

Enver Akalin, Vinita Sehgal, Scott Ames, Sabera Hossain, Lisa Daly, Murphy Barbara, Jonathan S. Bromberg

Research output: Contribution to journalArticlepeer-review

128 Scopus citations


The clinical patterns and predictors of cytomegalo-virus (CMV) disease in kidney and/or pancreas transplant patients on ganciclovir (1.0 g po t.i.d.) or valganciclovir (450 mg po q.d.) prophylaxis were studied. This is a retrospective analysis of 129 transplant recipients. Median follow up was 12 months (range, 6-18 months). The overall incidence of CMV disease at 1-year post-transplant was 14% (4% tissue-invasive, 10% noninvasive). Seventeen of 18 patients were diagnosed with CMV after completion of 3 months' prophylaxis (median 8 weeks, range, 2-28 weeks). Induction treatment with thymoglobulin, and Donor +/Recipient- CMV status were the strongest predictors for the development of CMV disease. Cytomegalovirus incidence was not different between patients treated with ganciclovir or valganciclovir (15 vs. 17%, respectively). Valganciclovir (450 mg q.d.) is as effective as oral ganciclovir in CMV prophylaxis. High-risk individuals might require higher doses or longer duration of valganciclovir treatment.

Original languageEnglish (US)
Pages (from-to)731-735
Number of pages5
JournalAmerican Journal of Transplantation
Issue number6
StatePublished - Jun 2003
Externally publishedYes


  • Cytomegalovirus
  • Ganciclovir
  • Thymoglobulin
  • Transplantation
  • Valganciclovir

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)


Dive into the research topics of 'Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis'. Together they form a unique fingerprint.

Cite this